FIG 3.
Subgroup analysis of rPFS and OS in the intention-to-treat population. Analysis of (A) rPFS per PCWG-modified RECIST 1.1 by blinded independent central review at the first interim analysis and (B) OS at the second interim analysis in key prespecified subgroups. CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; HRR, homologous recombination repair; NHA, next-generation hormonal agent; NR, not reached; OS, overall survival; PCWG, Prostate Cancer Working Group; PS, performance status; rPFS, radiographic progression-free survival.